Zacks Research Issues Optimistic Forecast for ENSC Earnings

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Stock analysts at Zacks Research lifted their Q3 2026 EPS estimates for shares of Ensysce Biosciences in a report issued on Tuesday, July 14th. Zacks Research analyst B. Sorensen now expects that the company will post earnings of $0.09 per share for the quarter, up from their prior estimate of ($0.49). The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($1.98) per share. Zacks Research also issued estimates for Ensysce Biosciences’ Q4 2026 earnings at ($0.60) EPS and FY2026 earnings at ($1.53) EPS.

Ensysce Biosciences (NASDAQ:ENSC) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.21. The business had revenue of $0.96 million during the quarter, compared to analysts’ expectations of $1.00 million. Ensysce Biosciences had a negative net margin of 250.39% and a negative return on equity of 766.45%.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Ensysce Biosciences in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Ensysce Biosciences Trading Down 4.8%

Shares of ENSC opened at $0.28 on Friday. The company has a market cap of $4.26 million, a price-to-earnings ratio of -0.08 and a beta of 0.78. The business’s fifty day simple moving average is $0.29 and its two-hundred day simple moving average is $0.49. Ensysce Biosciences has a 12 month low of $0.23 and a 12 month high of $2.75.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC purchased a new position in shares of Ensysce Biosciences during the third quarter valued at about $34,000. Virtu Financial LLC purchased a new stake in shares of Ensysce Biosciences in the third quarter worth about $34,000. DRW Securities LLC lifted its position in shares of Ensysce Biosciences by 42.4% in the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock worth $91,000 after buying an additional 29,336 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Ensysce Biosciences by 100.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after buying an additional 75,000 shares during the last quarter. 5.63% of the stock is currently owned by institutional investors.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.